Eli Lilly announced that Patrik Jonsson, executive vice president and president of Lilly International, will retire at the end of 2026 after a 36-year career. Starting January 1, 2027, Ilya Yuffa will take on an expanded role as executive vice president and president of Lilly Global Markets, overseeing worldwide customer strategy and execution. This change merges Lilly's U.S. and international businesses to improve decision-making and expand medicine access globally. Laura Steele and Elias Khalil will also be promoted to lead Lilly USA and Lilly Europe and Canada, respectively.
Eli Lilly's stock (LLY) trades at USD 1,282.00 on Pluang as of Oct 28, 2026 03:11 WIB, showing a modest 0.22% increase in the last day. The company holds a market cap of $1.14 trillion and a dividend yield of 0.54%. Pluang investors predominantly buy Eli Lilly shares, with 92% of order activity favoring purchases at this time.
In 2026, an S&P 500 index excluding AI-related stocks briefly outperformed the traditional S&P 500, reaching a 12.4% gain compared to the benchmark's 12%. This shift followed a sharp selloff in AI-linked tech stocks, which make up about 45% of the S&...
Eli Lilly's board announced a dividend of $1.73 per share for the fourth quarter of 2026, payable on December 10 to shareholders recorded by November 13. This dividend reflects the company's ongoing commitment to returning value to shareholders amid ...
Thermo Fisher Scientific reported 5% organic growth, surpassing consensus by 2 percentage points, prompting management to raise its full-year growth forecast. Mettler-Toledo's local-currency sales grew 6%, exceeding its previous 3% guidance. TEVA als...
Eli Lilly will report its Q3 2026 earnings on October 29, following five consecutive beats on earnings per share (EPS). The company showed strong revenue growth last quarter, driven by blockbuster drugs Mounjaro and Zepbound, with management raising ...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
